Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0288 Minireview: Lipid Metabolism, Metabolic Diseases, and
暂无分享,去创建一个
[1] Peter J. Brown,et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .
[2] C. Semenkovich,et al. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. , 2001, The Journal of clinical investigation.
[3] P. Edwards,et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[4] D. Mangelsdorf,et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. , 2000, Science.
[5] R. Evans,et al. Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.
[6] 窪田 直人. PPAR γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance , 2001 .
[7] Ingrid Pettersson,et al. Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity , 2002 .
[8] J. Lehmann,et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[9] Bruce A. Johnson,et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. , 2003, Molecular endocrinology.
[10] M. Matsuda,et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.
[11] J Auwerx,et al. PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.
[12] B. Spiegelman,et al. PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .
[13] S. Collins,et al. Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. , 1997, Biochemical and biophysical research communications.
[14] G. Watts,et al. Fibrates, dyslipoproteinaemia and cardiovascular disease. , 1999, Current opinion in lipidology.
[15] R. Evans,et al. PPARδ is a very low-density lipoprotein sensor in macrophages , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[16] W. Wahli,et al. Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting , 1999 .
[17] J. Auwerx,et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. , 1996, The Journal of clinical investigation.
[18] Daniel Metzger,et al. Impaired skin wound healing in peroxisome proliferator–activated receptor (PPAR)α and PPARβ mutant mice , 2001, The Journal of cell biology.
[19] C. Burant,et al. Troglitazone action is independent of adipose tissue. , 1997, The Journal of clinical investigation.
[20] G. Reaven. Syndrome X: 6 years later. , 1994, Journal of internal medicine. Supplement.
[21] A. Mahfoudi,et al. Positive regulation of the peroxisomal β‐oxidation pathway by fatty acids through activation of peroxisome proliferator‐activated receptors (PPAR) , 1993, Biology of the cell.
[22] R. Evans,et al. Peroxisome proliferator-activated receptor-γ in macrophage lipid homeostasis , 2002, Trends in Endocrinology & Metabolism.
[23] Barry M. Forman,et al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .
[24] P. J. Randle,et al. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. , 1998, Diabetes/metabolism reviews.
[25] M. Burge,et al. Thiazolidinediones: a comparative review of approved uses. , 2000, Diabetes technology & therapeutics.
[26] P. Scherer,et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.
[27] Andrew C. Li,et al. Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .
[28] D. Russell. Cholesterol biosynthesis and metabolism , 1992, Cardiovascular Drugs and Therapy.
[29] J. H. Johnson,et al. Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[30] P. J. Larsen,et al. PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly , 2003 .
[31] R. Evans,et al. Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[32] A. Kimmel,et al. Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. , 1999, Seminars in cell & developmental biology.
[33] W. Wahli,et al. Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. , 2002, Molecular cell.
[34] M. Lazar,et al. A futile metabolic cycle activated in adipocytes by antidiabetic agents , 2002, Nature Medicine.
[35] J. Olefsky,et al. TNF-α-Induced Insulin Resistance In Vivo and Its Prevention by Troglitazone , 1997, Diabetes.
[36] Satoshi Tanaka,et al. PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance , 1999 .
[37] J. Holder,et al. Repeat Treatment of Obese Mice With BRL 49653, a New Potent Insulin Sensitizer, Enhances Insulin Action in White Adipocytes: Association With Increased Insulin Binding and Cell-Surface GLUT4 as Measured by Photoaffinity Labeling , 1995, Diabetes.
[38] B. Spiegelman,et al. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.
[39] H. Ginsberg. New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism , 2002, Circulation.
[40] Xianlin Han,et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. , 2002, The Journal of clinical investigation.
[41] B. Spiegelman,et al. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. , 1997, The Journal of clinical investigation.
[42] L. Tecott,et al. Up-Regulation of Peroxisome Proliferator-Activated Receptors (PPAR-α) and PPAR-γ Messenger Ribonucleic Acid Expression in the Liver in Murine Obesity: Troglitazone Induces Expression of PPAR-γ-Responsive Adipose Tissue-Specific Genes in the Liver of Obese Diabetic Mice* * This work was supported by , 2000, Endocrinology.
[43] S. Kliewer,et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[44] J. Auwerx,et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[45] A. Tall,et al. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.
[46] W. Kraus,et al. Fatty Acid Homeostasis and Induction of Lipid Regulatory Genes in Skeletal Muscles of Peroxisome Proliferator-activated Receptor (PPAR) α Knock-out Mice , 2002, The Journal of Biological Chemistry.
[47] J. Auwerx,et al. 4.P.263 Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthetase (ACS) genes by PPARα and PPARγ activators , 1997 .
[48] W. Hsueh,et al. Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[49] D. Kelly,et al. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[50] H. Vosper,et al. The Peroxisome Proliferator-activated Receptor δ Promotes Lipid Accumulation in Human Macrophages* , 2001, The Journal of Biological Chemistry.
[51] R. Evans,et al. A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .
[52] J. Auwerx,et al. Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice* , 1997, The Journal of Biological Chemistry.
[53] P. Grimaldi,et al. Regulation of FAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid binding/transport. , 1997, Prostaglandins, leukotrienes, and essential fatty acids.
[54] R. Evans,et al. Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.
[55] J. Lehmann,et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.
[56] R. Evans,et al. PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.
[57] W. Wahli,et al. Critical roles of PPARβ/δ in keratinocyte response to inflammation , 2001 .
[58] L. Chao,et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. , 2000, The Journal of clinical investigation.
[59] B. Spiegelman,et al. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.
[60] J. Peters,et al. Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor α (PPARα)* , 1998, The Journal of Biological Chemistry.
[61] Y. Terauchi,et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.
[62] J. Auwerx,et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. , 2001, Molecular cell.
[63] T. Willson,et al. Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor γ Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive Tissues. , 2001, Endocrinology.
[64] S. Perrey,et al. Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice: Pleiotropic Effects on CD36 Expression and HDL , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[65] J. Lehmann,et al. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.
[66] M. Lazar,et al. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[67] K. Chien,et al. PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .
[68] T. Willson,et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. , 2001, Endocrinology.
[69] W. Wahli,et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.
[70] T. Pineau,et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.
[71] Xianlin Han,et al. A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[72] J. Ward,et al. Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ) , 2000, Molecular and Cellular Biology.